NLS drug-2

Toleranzia has announced that the toxicology study, conducted under Good Laboratory Practice (GLP), to enable first-in-human clinical trials, has been completed. The drug candidate was well tolerated at the dose tested, a finding fully supporting continued development of TOL2 and the submission of an application for the initiation of clinical trials in patients with myasthenia […]

The analysis of data from the phase IIa clinical study SPAGOPIX-02 with the contrast agent pegfosimer manganese confirms that the primary endpoint of measuring the MRI enhancing effect in endometriotic lesions was met, with an overall acceptable safety profile. “The promising results and conclusions from this first clinical trial with pegfosimer manganese in endometriosis strengthen […]

Mendus has reported positive updated survival data from the Phase 2 ADVANCE II trial evaluating vididencel in acute myeloid leukemia (AML). The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from the current standard of care in AML maintenance therapy, the company states. “We are obviously very pleased […]

BioInvent International has presented the first clinical data from a Phase 1/2a trial of its second FcyRIIB-blocking antibody BI-1607. BioInvent pipeline currently includes five drug candidates progressing through six clinical trials. The Phase 1 data The Phase 1 data covered 18 patients treated at doses ranging from 75 mg up to 900 mg flat dose. […]

Mendus has entered into a collaboration with the Australasian Leukaemia & Lymphoma Group (ALLG) to conduct a Phase 2 clinical trial, evaluating its lead product candidate vididencel in combination with oral azacitidine (AZA) as a potential novel maintenance treatment in acute myeloid leukemia (AML). Mendus and ALLG expect to obtain all approvals required for the […]

Abera Bioscience has concluded the last toxicological study with Ab-01.12 and received the final report, demonstrating that the vaccine is well-tolerated, has a good safety profile, and none of the tested doses resulted in lasting side effects. “These are gratifying results and a significant milestone for both our vaccine platform and the vaccine candidate. We […]